Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACAD Stock Forecast 2026-2027
$25.60
Current Price
$4.38B
Market Cap
Buy 16
Hold 4
Sell 1
Wall St Analyst Ratings
Distance to ACAD Price Targets
+75.8%
To High Target of $45.00
+34.8%
To Median Target of $34.50
-33.6%
To Low Target of $17.00
ACAD Price Momentum
-2.4%
1 Week Change
+18.4%
1 Month Change
+13.5%
1 Year Change
-4.2%
Year-to-Date Change
-9.7%
From 52W High of $28.35
+30.0%
From 52W Low of $19.69
📊 TOP ANALYST CALLS
Did ACAD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ACADIA Pharmaceuticals is one of their latest high-conviction picks.
Latest ACAD Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ACAD has a bullish consensus with a median price target of $34.50 (ranging from $17.00 to $45.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $25.60, the median forecast implies a 34.8% upside. This outlook is supported by 16 Buy, 4 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACAD Analyst Ratings
16
Buy
4
Hold
1
Sell
ACAD Price Target Range
Low
$17.00
Average
$34.50
High
$45.00
Current: $25.60
Latest ACAD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACAD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2026 | RBC Capital | Brian Abrahams | Outperform | Maintains | $36.00 |
| Jun 30, 2026 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $30.00 |
| Jun 29, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Jun 29, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 8, 2026 | Citigroup | Buy | Maintains | $N/A | |
| May 7, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 25, 2026 | B of A Securities | Buy | Upgrade | $N/A | |
| Mar 4, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Feb 27, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 26, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Feb 26, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Feb 26, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Feb 26, 2026 | Stifel | Hold | Maintains | $N/A | |
| Feb 24, 2026 | Wolfe Research | Outperform | Initiates | $N/A | |
| Feb 23, 2026 | Mizuho | Outperform | Upgrade | $N/A | |
| Feb 6, 2026 | Oppenheimer | Perform | Maintains | $N/A | |
| Feb 3, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Feb 3, 2026 | Citizens | Market Outperform | Reiterates | $N/A | |
| Feb 3, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 6, 2026 | Citigroup | Buy | Maintains | $N/A |
ACADIA Pharmaceuticals Inc (ACAD) Competitors
The following stocks are similar to ACADIA Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ACADIA Pharmaceuticals Inc (ACAD) Financial Data
ACADIA Pharmaceuticals Inc has a market capitalization of $4.38B with a P/E ratio of 11.6x. The company generates $1.10B in trailing twelve-month revenue with a 34.3% profit margin.
Revenue growth is +9.7% quarter-over-quarter, while maintaining an operating margin of -1.7% and return on equity of +37.3%.
Valuation Metrics
Market Cap
$4.38B
Enterprise Value
$3.64B
P/E Ratio
11.6x
PEG Ratio
-0.1x
Price/Sales
4.0x
Growth & Margins
Revenue Growth (YoY)
+9.7%
Gross Margin
+90.8%
Operating Margin
-1.7%
Net Margin
+34.3%
EPS Growth
-80.8%
Financial Health
Cash/Price Ratio
+19.4%
Current Ratio
3.6x
Debt/Equity
4.1x
ROE
+37.3%
ROA
+3.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ACADIA Pharmaceuticals Inc (ACAD) Business Model
About ACADIA Pharmaceuticals Inc
What They Do
Develops medicines for neurological disorders.
Business Model
Acadia Pharmaceuticals generates revenue through the commercialization of its FDA-approved therapies, primarily targeting conditions such as Parkinson's disease psychosis and Rett syndrome. The company also engages in clinical development programs, which may lead to additional revenue streams as new therapies are approved and brought to market.
Additional Information
Headquartered in San Diego, Acadia focuses on addressing significant unmet medical needs in the central nervous system space. The company leverages its proprietary research and regulatory expertise to develop specialized therapies for underserved neurological conditions, positioning itself as a key player in the biopharmaceutical market for neuroscience and orphan diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
796
CEO
Ms. Catherine E. Owen Adams
Country
United States
IPO Year
2004
Website
www.acadia.comACADIA Pharmaceuticals Inc (ACAD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
RPRX or ACAD: Which Is the Better Value Stock Right Now?
RPRX vs. ACAD: Which Stock Is the Better Value Option?
Jul 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
3 days ago
Quick Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will report Q2 2026 financial results on August 4, 2026, after market close, followed by a conference call at 4:30 p.m. ET.
Why It Matters
Acadia Pharmaceuticals' upcoming financial results and conference call may influence stock performance, providing insights on company health and future prospects, impacting investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Principal Accounting Officer James Kihara sold 11,421 shares for about $298,000 on June 26, 2026, decreasing his direct holdings by 46.60% to 13,088 shares.
Why It Matters
The significant sale of 46.60% of Kihara's holdings may signal potential concerns about the company's future performance, influencing investor sentiment and stock price.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Investors in Medical - Biomedical and Genetics sectors are considering Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD) as potential undervalued stock options.
Why It Matters
The comparison of Royalty Pharma and Acadia Pharmaceuticals highlights potential investment opportunities in undervalued biotech stocks, influencing portfolio strategies and stock selection.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Acadia Pharmaceuticals appointed Carl Segerstrom as Chief People Officer, effective July 6, to lead its global people and culture strategy amid growth in neurological and rare disease therapies.
Why It Matters
The appointment of Carl Segerstrom as Chief People Officer signals Acadia Pharmaceuticals' commitment to growth and enhancing company culture, which can positively impact employee performance and innovation in drug development.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Acadia (ACAD) experienced significant trading volume recently, but recent earnings estimate revisions may hinder its upward momentum in the near term.
Why It Matters
Acadia's increased trading volume signals heightened investor interest, but negative earnings estimate revisions could hinder future stock performance, indicating potential volatility.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Acadia stock rose 7% after the CHMP endorsed Daybu for EU approval in Rett syndrome, with a final decision from the European Commission expected soon.
Why It Matters
Acadia's stock surge indicates positive market sentiment and potential revenue growth from Daybu's EU approval for Rett syndrome, signaling increased investor confidence and future profitability.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ACAD Stock
What is ACADIA Pharmaceuticals Inc's (ACAD) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, ACADIA Pharmaceuticals Inc (ACAD) has a median price target of $34.50. The highest price target is $45.00 and the lowest is $17.00.
Is ACAD stock a good investment in 2027?
According to current analyst ratings, ACAD has 16 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $25.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACAD stock?
Wall Street analysts predict ACAD stock could reach $34.50 in the next 12 months. This represents a 34.8% increase from the current price of $25.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ACADIA Pharmaceuticals Inc's business model?
Acadia Pharmaceuticals generates revenue through the commercialization of its FDA-approved therapies, primarily targeting conditions such as Parkinson's disease psychosis and Rett syndrome. The company also engages in clinical development programs, which may lead to additional revenue streams as new therapies are approved and brought to market.
What is the highest forecasted price for ACAD ACADIA Pharmaceuticals Inc?
The highest price target for ACAD is $45.00 from at , which represents a 75.8% increase from the current price of $25.60.
What is the lowest forecasted price for ACAD ACADIA Pharmaceuticals Inc?
The lowest price target for ACAD is $17.00 from at , which represents a -33.6% decrease from the current price of $25.60.
What is the overall ACAD consensus from analysts for ACADIA Pharmaceuticals Inc?
The overall analyst consensus for ACAD is bullish. Out of 5 Wall Street analysts, 16 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $34.50.
How accurate are ACAD stock price projections?
Stock price projections, including those for ACADIA Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 5:10 PM UTC